MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc., a company developing protein and antibody therapeutics, announced today that it received a patent from the United States Patent and Trademark Office (US 7,317,091 B1) entitled, “Optimized Fc Variants,” expanding on the company’s rich patent estate for its proprietary Protein Design Automation® technology. This is the first issuance from a series of patent applications covering Xencor’s XmAb™ antibody Fc engineering technology, which is comprised of a suite of thousands of selectively engineered Fc domains. Xencor’s engineered Fc domains have been shown to improve antibody potency against tumor cells by more than 100-fold, significantly extend in vivo half-life and have been partnered with several large biotechnology and pharmaceutical companies to enhance specific clinical candidates.
